The companies collaborated to commercialize two cancer supportive care products i.e., Akynzeo (netupitant-palonosetron fixed combination) and Aloxi (palonosetron) for the prevention of CT-induced nausea and vomiting in core EU markets
Immedica will be responsible to commercialise Akynzeo in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg & Liechtenstein while ALOXI in Switzerland, Belgium, Liechtenstein
Akynzeo is the first 5-HT3 and NK1 receptor antagonist fixed combination & Aloxi has been approved in the EU for the same indication. Akynzeo & Aloxi is currently available in 60+ & 40+ countries, respectively
Ref: Globenewswire | Image: Helsinn
Related News:- Juniper Entered into an Exclusive License Agreement with Helsinn for Ledaga (chlormethine) to Treat Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma
